Kyntra Bio KYNB
NASDAQ KYNB
$3.20 -0.29 (-8.31%)
At close: Nov 16, 2026 · 4:00 PM EST

Kyntra Bio (KYNB) Asset Writedowns and Impairment (2023)

Updated

Kyntra Bio's Asset Writedowns and Impairment came in at $2.06 million for FY2025.

Analysis

Kyntra Bio (KYNB) Asset Writedowns and Impairment (2023) Analysis & Trends

  • Per Business Quant, earlier years put Asset Writedowns and Impairment at $1 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn
10 Kyntra Bio 12.57 Mn -395.37 Mn 1.47 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2023 1.00 Mn
API Access

Kyntra Bio Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=KYNB&period=max&api_key=YOUR_API_KEY